Comparing Maintenance Regimens and Treatment Selection Factors in ES-SCLC

Dr. Leal outlines current decision-making, noting lurbinectedin plus atezolizumab represents the approved standard frontline maintenance strategy for patients tolerating induction well, achieving stable disease or response, and motivated for treatment intensification. She acknowledges some patients will choose immunotherapy alone after weighing risks and benefits.

Without direct comparative data, cross-trial comparisons become necessary. The IMforte regimen showed approximately 38% dose holds/modifications with only 6% discontinuation, suggesting effective management of myelosuppression-related toxicities through dose adjustments while patients continue benefiting.

Regarding tarlatamab-based maintenance infrastructure requirements, current protocols require 22- to 24-hour inpatient observation for initial doses. Dr. Leal describes successful community partnerships where patients receive first doses at academic centers like Emory before transitioning back to community practices for subsequent treatment, anticipating this infrastructure development could be established during induction for first-line maintenance implementation.

Dr. Sands differentiates toxicity considerations: lurbinectedin's cytotoxic profile causes longer-term fatigue and functional decline concerns in frail patients, whereas tarlatamab doesn't cause this cytotoxicity pattern. He's more willing to treat symptomatic patients with tarlatamab given potential functional status improvement and demonstrated durability beyond 1 year. Patient-specific factors like history of seizures requiring caution with ICANS risk, patient support systems, and individual circumstances ultimately guide personalized regimen selection between these emerging options.